Warnings of recession are widespread, inflation is still elevated and so are interest rates. Russia continues to wage war in Ukraine and markets are whipsawing around as investors try to make sense of it all. In short: The global macroeconomic picture is bleak.
In spite of it all, dealmaking on Wall Street appears to be making a comeback. There have been 39 US initial public offerings (IPOs) priced so far this year, according to data from research firm Renaissance Capital, a 77% change from the same period in 2022.
So why is this happening? The banking crisis caused by the recent collapse of Silicon Valley Bank and Signature Bank could be the cause.
Regional banking turmoil has led to tighter credit conditions which could push some companies to go public, said Barrett Daniels, US IPO co-leader at Deloitte. Without access to loans from banks and private equity, companies need to get money somewhere. Selling shares to investors is a way to do that.
"It's all on the table right now," said Daniels. "Nobody wants to see a bunch of companies going out of business."
The recent boost in activity is unusual. Dealmaking typically booms when markets are stable and businesses feel good. When the economy swoons, companies like to rein in public offerings and takeover activity.
Case in point: The IPO market went from boom to bust in 2022 — global IPO activity was cut nearly in half and things were even worse in the United States, where 149 IPOs launched compared to 908 in 2021. Over the same period, the S&P 500 fell by more than 18%.
Now, a wave of optimism is washing over the market. "Despite the unforgiving economic and geopolitical backdrop, there is light on the horizon with peaking inflation, energy prices softening and the rebound of mainland China's economy," wrote EY analysts in a note.
A lot of companies hit pause on plans to go public last year, hoping to make their market debut during more bullish times, said Daniels.
The IPO pipeline is full. Daniels has said previously that there are more than 1,000 companies worth over $1 billion that are prepared to go public, but are waiting for the economy to clear up first. That may happen sooner rather than later, he said.
"It seems like there's a consensus that the fourth quarter [of 2023] is a starting point for an IPO market recovery," Daniels said. "When it does open up, it's going to be gangbusters."
A few successful offerings could be all it takes to turn the stream from a drizzle into a full on deluge, he said.
That's why investors are closely watching Johnson & Johnson's spinoff of its consumer business, Kenvue.
Kenvue will house a portfolio of household brands like Tylenol, Band-Aid, Aveeno, Neutrogena, Listerine and Johnson's. In a filing on Monday, the company said it plans to price shares at $20 to $23 in an IPO later this year.
The spinoff would be valued at around $40 billion, making it the largest offering so far this year.
It's not just IPOs. Mergers and acquisitions in the healthcare industry have totaled more than $119.6 billion so far this year, that's up 62% from this time a year ago, according to data from Refinitiv. Globally, follow-on offers (when a company issues more shares to raise extra capital) are up about 22% compared to last year.
IPOs and M&A activity mean big money for financial firms that earn significant fees for facilitating these transactions. Increased activity means bigger bonuses and a stronger financial sector.
Comments
Post a Comment